I also don't understand why people complain about low number of sales. The company even announced recently that there will be no significant sales throughout the whole year 2006. The most recent projection of Calypte does say so.
There are hundreds of listed biotechs which burn money (and are well respected). Being not profitable is not bad per se but could be part of a development process. Serious people who are invested in this company do not expect sales this summer but in the future. The only relevant issue to discuss is whether there will be sales in the future or not.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.